Last reviewed · How we verify
NCT07119541
Testing an Alliance-Focused Dialectical Behaviour Therapy Training for Borderline Personality Disorder
NA trial testing Alliance-Focused Dialectical Behavior Therapy plus Deliberate Practice in Borderline Personality Disorder in 80 participants. Participants enrolled and being followed up; not accepting new ones.
28 November 2025
Quick facts
| Lead sponsor | York University |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | health services research |
| Enrollment | 80 |
| Start date | 1 August 2025 |
| Primary completion | 28 November 2025 |
| Estimated completion | 31 January 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Alliance-Focused Dialectical Behavior Therapy plus Deliberate Practice
- Alliance-Focused Dialectical Behavior Therapy plus Reflective Practice
Conditions studied
- Borderline Personality Disorder — all drugs for Borderline Personality Disorder →
- Emotion Dysregulation — all drugs for Emotion Dysregulation →
Sponsor
York University
Who can join
18 and older, any sex, with Borderline Personality Disorder or Emotion Dysregulation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study evaluates the feasibility, acceptability, and effect sizes of two alliance-focused dialectical behavior therapy (DBT) training interventions to improve therapists' abilities to recognize and respond to alliance ruptures with clients with borderline personality disorder (BPD). Participants will be randomly assigned to receive either a 4-week training as usual (TAU), which include didactic training plus reflective practice (i.e., thinking about past actions to gain insight for future actions) or a 4-week didactic training plus deliberate practice training (i.e., setting individualized training goals, skills coaching, and opportunities for repeated practice with expert feedback). A pre-post design will be used to assess effect sizes for change in participants' abilities to recognize and respond to alliance ruptures. Therapist characteristics will be assessed to determine moderating effects on training outcome. Feasibility and acceptability of the training intervention will be assessed following the trainings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07119541
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Borderline Personality Disorder
Currently open trials in the same condition.
- NCT06458933 — Testing Interventions for Borderline Personality Disorder. · Phase 2 · recruiting
- NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
- NCT06446765 — Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder · Phase 2 · recruiting
- NCT07197502 — Treatment of Borderline Personality Disorder With rTMS · NA · recruiting
- NCT06772831 — Cognitive Reappraisal Training for Borderline Personality (BPD) · NA · recruiting
Other York University trials
Trials by the same sponsor.
- NCT07513987 — IMPACT: Immune and Musculoskeletal Physiological Adaptations to Combined Exercise Training & Nutrition · NA · not yet recruiting
- NCT07312409 — Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID? · NA · not yet recruiting
- NCT07418320 — Grow Together, Thrive Together: A Feasibility Study of a Brief Relationship Intervention for Emerging Adults and Their C · NA · not yet recruiting
- NCT07351630 — Building Blocks for Child and Family Well-being · NA · recruiting
- NCT06458933 — Testing Interventions for Borderline Personality Disorder. · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07119541 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by York University
- Last refreshed: 2 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07119541.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing